Next Phase Newsletter

A corporate venture firm founded in 2020 is headquartered in Denver, Colorado. The firm’s typical check size ranges from $1-10M in Seed stage and beyond, with Series A being their sweet spot. Because of the flexibility in their balance sheet and investment committee, the firm has also looked at investments greater than $10M in Series C and D companies. The firm typically makes equity investments but has used notes for later stage investments. The firm is USA focused but will look at companies headquartered elsewhere if there’s USA commercial traction or intent to commercialize in the US.

The firm is interested in diagnostic and digital health sectors and is open to all subsectors and indications. The firm is not interested in therapeutics or medical devices, unless they’re noninvasive medical devices. The firm is especially interested in technology that impacts their polychronic patients, especially since the firm has a strong intention of moving upstream into the CKD and ESKD space. The firm has done a lot of work in the cardiometabolic and comorbidity space, more specifically looking at technology for cardiovascular disease, diabetes, COPD, social determinants of health, end of life and behavioral health.

The firm prefers management teams with entrepreneurial experience but is open to all types of management teams and has backed first-time founders. For companies not in the diagnostics or device space, The firm likes to see at least $1M in ARR. The firm has led in the past but prefers to join syndicates.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A venture capital firm with multiple offices in the USA partners with and invests in entrepreneurs who are developing breakthrough products leveraging the convergence of biology and/or hardware with advanced computation and AI (referred to as Convergent Tech). The firm employs a multi-stage investment strategy, encompassing both seed and venture investment programs, and assist entrepreneurs with recruiting and customer and supply chain business development. The firm is generally a lead investor, and invests up to $10 million per opportunity; the firm also has an active seed fund that invests smaller amounts at earlier development stages.

The firm invests in life science start-ups developing advanced materials, process, and device technologies that leverage advanced computational approaches such as deep learning, and unique data generation capabilities. Specific areas of interest include drug discovery platforms, manufacturing platforms, drug delivery platforms, non-invasive diagnostics, and sustainability generally. The firm does not invest in pure-play therapeutic clinical development business models.

The firm favors companies with platform technologies and partnership-based business models. The firm has deep expertise in manufacturing and productization. Additionally, LPs include large pharma and medical device manufacturing companies; Phoenix Venture Partners helps portfolio companies develop relationships with these strategics.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in USA and Singapore makes early up to expansion stage investments across several industries including healthcare. The investment size is highly variable depending on the stage of the company. The firm invests in companies in North America and Europe that has a market expansion strategy in Asia and/or Singapore. The firm is actively seeking new investment opportunities.

In the Life Sciences, the firm is currently seeking medical devices, synthetic biology and HCIT. For medical devices, the firm is opportunistic in terms of subsectors and indications. The firm looks for devices that are ready for commercialization. The firm is currently not looking for drug development companies.The firm seeks entrepreneurs who are passionate, driven and enthusiastic, with sustainable business models and ideas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA is interested in a broad range of technology companies, including those in the software, cloud services, IT, and Internet sectors. In the life sciences, the firm will only invest in the healthcare IT sector. The firm invests in late seed to early Series A rounds with a typical investment size ranges from $1M-$5M. Investment is typically in form of equity, though convertible notes would be considered as well. The firm will look at investment opportunities across the US West Coast and in Texas.

The firm will make new investments in the digital health sector. The firm is interested in healthcare services and IT companies targeting platform, enterprise software, m-health, solution, data analytics and consumer health. The firm will invest in commercial-stage companies with products or services on the market.

The firm invests in privately held healthcare companies. The firm focuses on companies with annual revenues of between $0.5M and $10M.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm headquartered in Europe, with additional offices in USA and Asia seeks to invest in innovations directly related to the prevention of age-associated diseases, extension of a healthy lifespan, and improving the performance of humans and animals. The firm’s initial check size can range from $500K – 1.5M, and the firm is open to global opportunities.

Within life sciences, the firm is most interested in therapeutics and diagnostics companies, and will also consider digital health. Medical devices with traditional regulatory pathways are generally out of scope for the firm. Within these sectors, interest areas can include gene therapy, telomere attrition, proteostasis, regenerative medicine, personalized diagnostics/biomarkers, preventative therapies, cognitive enhancement, and more. That said, the firm has no strong interest in particular technologies and is open to all modalities. The firm is also opportunistic in terms of stage of development.

The firm seeks companies with strong, protectable IP with clear origins and ownership, backed by a diverse team with a strong track record and technologies with validated proof of concept. The firm has a 3-step due diligence process which includes: (1) initial review, (2) additional review – where the firm looks more closely into main differentiating factors of the company (IP, business model, etc.), and (3) final review. The firm is open to leading, co-leading, or co-investing, and has a strong co-investment and syndication network of likeminded investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm was founded in 1965 and is based in California, USA. The firm invests in seed and early-stage digital health and therapeutic companies. The typical investment size for seed investment ranges from $500K to $1M (usually in equity or capped, convertible notes). For early-stage companies, the firm typically co-invests with other VC firms in Seed and Series A financing and the investment size will depend on the company’s financial needs. The firm is geographically agnostic but prefers start-ups to be based in the United States. The firm is actively seeking new investment opportunities.

The firm is actively seeking new investment opportunities in the digital health sector and areas of interest include: Precision medicine, digital therapeutics, combination data products, scalability solutions and clinical trial management solutions.

The firm often leads financings and takes a board seat, but prefers to syndicate on opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The firm is a venture capital firm that was founded in 2005 and it is based in Germany. The firm with about EUR 900 million under management currently invests out of its third fund. The firm focuses on investments in technology-based early stage companies in life science industry among other technologically oriented industries. The venture capitalist provides initial investments of up to EUR 600,000-1 million. The firm will also reserve a further EUR 3 million for follow-on financing and supports the start-ups in acquiring other investors and partners. The firm is interested in companies that have been in operation for less than one year. The firm typically targets 12-15 life science investments per year. The firm invests primarily in Germany but also has the capacity to invest in other parts of Europe with ties to Germany. For the first investment, startups should be less than 3 years old. 

The firm is looking for new opportunities in the life science space including therapeutics, diagnostics, medical devices, material sciences, chemicals, regenerative energies and healthcare IT sectors. The firm is opportunistic in terms of sector, subsectors and indications, but it focuses on companies with a significant technological innovation or business model and close to proof of concept. The firm’s investments to date have included life science companies developing medical devices, vaccines, drugs development, diagnostic services, chemicals and platform technologies. 

The firm only invests in seed-stage companies located in Germany (or at least with ties to Germany: money spend there). The founding team should have the relevant know-how, complimentary skills and relevant business / industry experience. Outside of Germany, the firm only invests as a co-investor alongside a local investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.